IDEAYA Biosciences $92 million follow-on offering
Davis Polk advised the underwriters in connection with a public offering of 5,333,333 shares of common stock of IDEAYA Biosciences, Inc. at $17.25 per share, which included 695,652 shares from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of $92 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IDYA.”
Based in South San Francisco, California, IDEAYA is a clinical stage oncology-focused precision medicine company developing targeted therapeutics for patients selected using molecular diagnostics across multiple oncology indications.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye, Paula Gergen and Lawrence Edward Traylor Jr. The tax team included partner Po Sit and associate Ben Levenback. The intellectual property and technology transactions team included partner David R. Bauer and associate S. Dream Montgomery. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.